OLGXF News Alert Osteologix Holdings (OLGXF) 0.0075 02/15/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Osteologix Holdings (OLGXF) 0.0075 $OLGXF

Post Menopausal Osteoporosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/kgcd25/post_menopausal) has announced the addition of the "Post Menopausal Osteoporosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Merck & Co - Pfizer - Osteologix Holdings - Unigene Laboratories - Radius Health - Chronos Therapeutics - Amgen Astellas BioPharma - Paras Biopharmaceuticals Finland For more information visit http://www.researchandmarkets.com/research/kg...menopausal
RDUS: 50.37 (+0.63), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30)

Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 65

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 29

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 65

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 53

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 164

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 40

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

Synovus Appoints New Chattanooga Market Leader for Growth

Updated Category News Views 502

Synovus Appoints Jim Vaughn as Chattanooga Market Executive Synovus has recently made headlines by appointing Jim Vaughn as the new Chattanooga market executive. He brings a wealth of experience and has a solid background in the financial sector, joining from Mauldin & Jenkins, where he honed his skills over a significant tenure. Leadership Role and Responsibilities In...

Continue Reading
Navigating Recruitment Trends in Maritime and Oil & Gas for 2025

Updated Category News Views 85

Trends Shaping Recruitment in the Maritime and Oil & Gas Industries Core Group Resources stands at the forefront of talent acquisition, guiding businesses toward sustainable growth by effectively identifying and nurturing the right talent. As we approach 2025, the company has unveiled a comprehensive analysis detailing the pivotal trends that will influence recruitment...

Continue Reading
Disney and Netflix Stocks Dip Amid Warner Bros. Merger News

Updated Category News Views 430

Disney and Netflix Stocks Experience a Decline Securities of Walt Disney Co (NYSE: DIS) and Netflix Inc (NASDAQ: NFLX) are witnessing a downward trend, likely influenced by recent reports concerning a significant business maneuver involving Warner Bros. Discovery Inc (NASDAQ: WBD). Speculation arises that a coalition led by Paramount Skydance Corp (NASDAQ: PSKY) is...

Continue Reading
Alpine Income Property Trust Launches New Preferred Stock Offering

Updated Category News Views 136

Alpine Income Property Trust Announces Public Offering Alpine Income Property Trust, Inc. (NYSE: PINE) has officially announced the launch of its public offering for the Series A Cumulative Redeemable Preferred Stock, which has a liquidation preference of $25.00 per share. This initiative reflects the company’s strategic approach to expanding its capital base and...

Continue Reading
Civitas Capital Strengthens Team with New Regional Director

Updated Category News Views 127

Civitas Capital Welcomes Rishabh Gandhi Civitas Capital is thrilled to announce a significant addition to our team: Rishabh Gandhi, who joins us as Regional Director for India and the Middle East. With over nine years of invaluable experience in the EB-5 investment industry, Rishabh brings a wealth of expertise, strategic insight, and an established network of...

Continue Reading